Last reviewed · How we verify
1- Insulin glargine QHS
At a glance
| Generic name | 1- Insulin glargine QHS |
|---|---|
| Also known as | Trade name: Lantus |
| Sponsor | Charles Drew University of Medicine and Science |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
- Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control (PHASE3)
- Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (PHASE3)
- Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) (PHASE4)
- Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery (PHASE4)
- A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus (PHASE3)
- Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1- Insulin glargine QHS CI brief — competitive landscape report
- 1- Insulin glargine QHS updates RSS · CI watch RSS
- Charles Drew University of Medicine and Science portfolio CI